EP. 1: HER2-Mutant NSCLC: Emerging Therapeutic Landscape and Clinical Implications
May 28th 2025
On May 6, 2025, a select group of US medical oncologists and 1 radiation oncologist from academic and cancer specialty institutions participated in a virtual workshop to discuss insights and considerations for identifying and managing HER2-mutant non–small cell lung cancer (NSCLC). The session was moderated by Joshua K. Sabari, MD, who obtained perspectives on testing for and management of HER2 NSCLC and recent trials of antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) for the treatment of HER2-mutant NSCLC.
